Royal Philips (NYSE:PHG) announced today, December 15, 2025, that it has reached an agreement to acquire SpectraWAVE, a Bedford, Massachusetts-based innovator in intravascular imaging and physiological assessment.
The strategic acquisition will immediately fortify Philips’ portfolio for interventional cardiology by incorporating SpectraWAVE's advanced, AI-enabled technologies.
The deal centers on two key product lines developed by SpectraWAVE: the HyperVue Imaging System, which combines DeepOCT (Deep Optical Coherence Tomography) and NIRS (Near-Infrared Spectroscopy) for detailed coronary plaque assessment, and X1-FFR, an angiography-derived, Artificial Intelligence (AI)-enabled Fractional Flow Reserve (FFR) software solution.
The integration will see these new capabilities merged with Philips’ established Azurion image-guided therapy platform, alongside existing devices such as the Eagle Eye Platinum IVUS and OmniWire iFR.
This move aims to create a more comprehensive and streamlined toolkit for clinicians treating coronary artery disease.
While financial terms of the agreement were not disclosed, the acquisition brings on SpectraWAVE’s team of approximately 70 employees.
Both the HyperVue and X1-FFR products have secured US FDA Class 2 clearances, making them immediately ready for integration into the Philips workflow.
Philips’ leadership framed the transaction as a commitment to expanding its clinical options for image-guided therapy, stating that the addition of SpectraWAVE's high-definition imaging and wire-free physiology assessment tools will enable better care for a wider patient population.